<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03642067</url>
  </required_header>
  <id_info>
    <org_study_id>J18119</org_study_id>
    <secondary_id>IRB00173537</secondary_id>
    <secondary_id>CA224-068</secondary_id>
    <nct_id>NCT03642067</nct_id>
  </id_info>
  <brief_title>Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer</brief_title>
  <official_title>Phase A Phase 2 Study Evaluating Response and Biomarkers in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer Treated With Nivolumab in Combination With Relatlimab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and clinical activity of nivolumab and&#xD;
      relatlimab in patients with metastatic or locally advanced microsatellite stable (MSS)&#xD;
      colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 12, 2019</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>4 years</time_frame>
    <description>The proportion of subjects with partial response (PR) or complete response (CR) according to RECIST 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing study drug-related toxicities</measure>
    <time_frame>4 years</time_frame>
    <description>Number of participants experiencing study drug-related adverse events Grade 3 or higher as defined by CTCAE v5.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Microsatellite Stable (MSS) Colorectal Adenocarcinomas</condition>
  <condition>Colorectal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Cohort A/B: Nivolumab and Relatlimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>480mg/160mg (co-administered)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C: Nivolumab and Relatlimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>480mg/ 960mg (sequential administration)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Patients will receive treatment every 28 days for up to 2 years. Nivolumab will be administered IV on day 1 (28 day cycle).</description>
    <arm_group_label>Cohort A/B: Nivolumab and Relatlimab</arm_group_label>
    <other_name>anti-PD-1, OPDIVO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Relatlimab</intervention_name>
    <description>Patients will receive treatment every 28 days up to 2 years. Relatlimab will be administered IV on day 1 (28 day cycle).</description>
    <arm_group_label>Cohort A/B: Nivolumab and Relatlimab</arm_group_label>
    <other_name>BMS-986016</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Patients will receive treatment every 28 days for up to 2 years. Nivolumab will be administered IV on day 1 (28 day cycle).</description>
    <arm_group_label>Cohort C: Nivolumab and Relatlimab</arm_group_label>
    <other_name>anti-PD-1, OPDIVO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Relatlimab</intervention_name>
    <description>Patients will receive treatment every 28 days up to 2 years. Relatlimab will be administered IV on day 1 (28 day cycle).</description>
    <arm_group_label>Cohort C: Nivolumab and Relatlimab</arm_group_label>
    <other_name>BMS-986016</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years.&#xD;
&#xD;
          -  ECOG performance status 0 or 1&#xD;
&#xD;
          -  Have metastatic or locally advanced microsatellite stable (MSS) colorectal&#xD;
             adenocarcinoma.&#xD;
&#xD;
          -  Cohort A: Primary lesion has a composite PD-L1/Mucin (CPM) score ≥ 15%.&#xD;
&#xD;
          -  Cohort B: Primary lesion has a composite PD-L1/Mucin (CPM) score &lt; 15%.&#xD;
&#xD;
          -  Cohort C: Prior surgical resection of primary tumor. Prospective biomarker evaluation&#xD;
             not required.&#xD;
&#xD;
          -  Must have received at least one chemotherapy regimen.&#xD;
&#xD;
          -  Patients with the presence of at least one measurable lesion using RECIST 1.1.&#xD;
&#xD;
          -  Patients must have available archival tissue from the surgical resection of their&#xD;
             primary tumor.&#xD;
&#xD;
          -  Patient's acceptance of tumor biopsies.&#xD;
&#xD;
          -  Life expectancy of greater than 3 months.&#xD;
&#xD;
          -  Patients must have adequate organ and marrow function defined by study - specified&#xD;
             laboratory tests.&#xD;
&#xD;
          -  Documented LVEF ≥ 50% - 6 month prior to drug administration.&#xD;
&#xD;
          -  Must use acceptable form of birth control while on study.&#xD;
&#xD;
          -  Ability to understand and willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known history or evidence of brain metastases. Patients with previously treated brain&#xD;
             metastases may participate if they are stable for 4 weeks prior to beginning&#xD;
             treatment, have no new or enlarging brain metastases, and are not using steroids for&#xD;
             at least 1 week prior to initiation of study treatment.&#xD;
&#xD;
          -  Require any antineoplastic therapy.&#xD;
&#xD;
          -  History of prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4, or&#xD;
             anti-Lag-3 antibodies.&#xD;
&#xD;
          -  Had chemotherapy, radiation, or steroids within 14 days prior to study treatment.&#xD;
&#xD;
          -  Had any cytotoxic drug within 4 weeks prior to initiation of study treatment.&#xD;
&#xD;
          -  Hypersensitivity reaction to any monoclonal antibody.&#xD;
&#xD;
          -  Has uncontrolled intercurrent acute or chronic medical illness.&#xD;
&#xD;
          -  Has an active known or suspected autoimmune disease.&#xD;
&#xD;
          -  Has a diagnosis of immunodeficiency.&#xD;
&#xD;
          -  Prior tissue or organ allograft or allogeneic bone marrow transplantation.&#xD;
&#xD;
          -  Requires daily supplemental oxygen&#xD;
&#xD;
          -  History of interstitial lung disease.&#xD;
&#xD;
          -  Significant heart disease&#xD;
&#xD;
          -  History of encephalitis, meningitis, or uncontrolled seizures in the year prior to&#xD;
             informed consent.&#xD;
&#xD;
          -  Infection with HIV or hepatitis B or C at screening.&#xD;
&#xD;
          -  Has an active infection.&#xD;
&#xD;
          -  Unable to have blood drawn.&#xD;
&#xD;
          -  Patient with uncontrolled intercurrent illness including, but not limited to,&#xD;
             uncontrolled infection, symptomatic congestive heart failure, unstable angina&#xD;
             pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would&#xD;
             limit compliance with study requirements.&#xD;
&#xD;
          -  Woman who are pregnant or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dung Le, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trish Brothers, RN</last_name>
    <phone>410-614-3644</phone>
    <email>GIClinicalTrials@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joann Santmyer, RN</last_name>
    <phone>410-583-2970</phone>
    <email>GIClinicalTrials@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Sartorius-Mergenthaler, RN</last_name>
      <phone>410-614-3644</phone>
      <email>Sartosu@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Joann Santmyer</last_name>
      <phone>410-583-2970</phone>
      <email>jsantmy1@jhmi.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 15, 2018</study_first_submitted>
  <study_first_submitted_qc>August 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2018</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relatlimab</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Anti-PD-1</keyword>
  <keyword>Anti-LAG-3</keyword>
  <keyword>Antibody</keyword>
  <keyword>MSS</keyword>
  <keyword>PD-L1</keyword>
  <keyword>Microsatellite stability</keyword>
  <keyword>Colorectal cancer</keyword>
  <keyword>Colon cancer</keyword>
  <keyword>Rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

